PHARMACEUTICAL distributor RA Williams Distributors Limited is actively exploring opportunities to expand its operations across the wider Caribbean, even as it continues to build out its treatment pipeline.

Speaking at the company’s first annual general meeting last week, CEO Audley Reid said that management is carefully plotting the steps to make regional expansion a reality.

“We see potential in smaller Caribbean markets where access to medicines is still not fully reliable. These are markets that are too small for big multinationals to prioritise but they fit us well as they’re agile, reliable, and relationship-driven. We’re not rushing into it, but we’re laying the groundwork,” he told shareholders.

“For now, Jamaica remains our anchor but the region is certainly part of our future,” he added.

As a publicly listed entity, on the heels of a solid first-year performance in which the company secured revenues of $1.6 billion and a net profit of $28.6 million, the company’s directors said it remains bullish on embarking on the next chapter of growth.

Despite recording a short-term loss during the first quarter which was tied to increased growth-related expenses, the directors said the company’s near doubling of its equity base will significantly help to boost its ability to capitalise on upcoming opportunities.

For the quarter ended July 31, 2025 RA Williams reported a net loss of $1.9 million, compared to a net profit of $24.1 million in the corresponding period of last year. Total revenues, however, climbed 7.6 per cent to $417 million, supported by stronger demand and the successful integration of new pharmaceutical product lines. Among them was the epilepsy treatment drug Iracet, along with some six other new products introduced in late 2024 — all of whose addition the company said have positioned it for stronger revenue performance in the current financial year.

RA Williams also expanded its distribution network and product portfolio by securing the exclusive rights to distribute Fourrts India Laboratories’ products in Jamaica. Additionally, it became the second official distributor for Canadian based outfit Ryvis Pharma on the island.

Listed on the Junior Market of the Jamaica Stock Exchange (JSE) in August 2024, RA Williams is a family owned company that began as a small, rural pharmacy and has since evolved into a nationwide distributor. Founded by pharmacists in 2012 it now supplies a wide range of prescription and over-the-counter medications to pharmacies and health-care providers islandwide. The company is currently awaiting the necessary regulatory approval for several additional therapies it plans to introduce.

According to Reid, these new offerings will help to broaden treatment options for chronic conditions while making care more affordable — particularly in underserved areas.

“We are currently working to secure regulatory approvals for a pipeline of new medications so that we can introduce more cutting edge therapies to the Jamaican market,” Reid said. “Our focus is always on expanding the reach of care. By bringing new therapies to the market we can ensure better access and better outcomes for patients.”

Listed on the Junior Market of the Jamaica Stock Exchange (JSE) in August 2024, RA Williams is a family-owned company that began as a small rural pharmacy and has since evolved into a nationwide distributor.